Free Trial

UCB (OTCMKTS:UCBJF) Sees Unusually-High Trading Volume - Here's Why

UCB logo with Medical background

Key Points

  • UCB SA's stock saw an impressive 772% increase in trading volume, with 7,729 shares exchanged compared to just 886 shares in the previous session.
  • Morgan Stanley has upgraded UCB shares to an "overweight" rating, reflecting positive sentiment among Wall Street analysts.
  • The stock is currently trading at $213.80, having previously closed at $219.79, with its 50-day and 200-day moving averages at $195.22 and $184.13 respectively.
  • MarketBeat previews top five stocks to own in September.

Shares of UCB SA (OTCMKTS:UCBJF - Get Free Report) saw strong trading volume on Friday . 7,729 shares changed hands during mid-day trading, an increase of 772% from the previous session's volume of 886 shares.The stock last traded at $213.80 and had previously closed at $219.79.

Wall Street Analyst Weigh In

Separately, Morgan Stanley raised shares of UCB to an "overweight" rating in a report on Monday, June 23rd.

Get Our Latest Analysis on UCBJF

UCB Price Performance

The business's 50-day simple moving average is $195.22 and its two-hundred day simple moving average is $184.13. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78.

About UCB

(Get Free Report)

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in UCB Right Now?

Before you consider UCB, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UCB wasn't on the list.

While UCB currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Value Plays Set to Explode
5 Stocks to BUY NOW in August 2025
The $2.5B Merger No One Is Talking About

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines